Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition

  • Autoimmune Disorder
  • Multiple Sclerosis (MS)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Country
  • Spain
Trial Identifier:

NCT02598167 ML29715

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This multi-center non-interventional, observational, cross-sectional study in adult participants with relapsing remitting multiple sclerosis (RRMS) will evaluate the participants' preferences for disease modifying treatments (DMT) in routine clinical practice.

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT02598167, ML29715 Trial Identifier
      Multiple Sclerosis, Relapsing-Remitting Condition
      Official Title

      Assessing Patients Preferences Towards Disease-modifying Therapeutic Options in Relapsing Remitting Multiple Sclerosis

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants aged greater than or equal to (>/=) 18 years
      • Participants who have a diagnosis of RRMS as documented in their medical records
      • Participants who have been prescribed a DMT for at least 3 months
      • Participants who have an expanded disability status scale (EDSS) score of 1-6 points
      Exclusion Criteria
      • Participants with any personal or medical condition that in opinion of the investigator would interfere with or make impossible proper participation in the study

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on ForPatients in related disease areas.

      Multiple Sclerosis (MS)

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now